Sarepta Therapeutics, Inc. SRPT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Elevidys | $625.71M-30.4% | $898.73M-23.3% | $1.17B-4.0% | $1.22B+15.1% | $1.06B+1.5% | |
| Pmo Products | $957.58M-0.8% | $965.57M+0.5% | $960.36M-1.1% | $970.6M-0.8% | $978.16M+1.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Sarepta Therapeutics, Inc. break its business down?
- Sarepta Therapeutics, Inc. (SRPT) reports revenue by product across 2 parts — Elevidys and Pmo Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Sarepta Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Sarepta Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.